JACK W. LASERSOHN - 17 Sep 2024 Form 4 Insider Report for Silk Road Medical Inc

Role
Director
Signature
/s/ Mhairi Jones, by power of attorney
Issuer symbol
N/A
Transactions as of
17 Sep 2024
Net transactions value
-$66,825
Form type
4
Filing time
18 Sep 2024, 21:01:12 UTC
Previous filing
21 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SILK Common Stock Disposed to Issuer -16,735 -100% 0 17 Sep 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SILK Stock Option (right to buy) Disposed to Issuer $66,825 -8,910 -100% $7.50 0 17 Sep 2024 Common Stock 8,910 $20.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

JACK W. LASERSOHN is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
F2 Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
F3 Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
F4 The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.